A feature published in The Lancet Infectious Diseases - Antibiotic development pipeline slows to a trickle - cites The Life Prize as one of the latest mechanisms for the development of new and essential drugs to combat tuberculosis (TB).
A feature published in The Lancet Infectious Diseases (November 2017) - Antibiotic development pipeline slows to a trickle – follows up the findings of a recent report by the World Health Organization (WHO) on the global scarcity of the antibacterial drug pipeline, and cites The Life Prize as one of the latest mechanisms for the development of new and essential drugs to combat tuberculosis (TB).
The article says, “The Life Prize (formerly the 3P Project) is an attempt to kickstart the development of new antibiotics and treatment combinations for TB using a coordinated system of research grants, prizes, and pooled intellectual property.”
The Life Prize aims to unite researchers to collaborate and develop a one-month (or less) treatment regimen for all types of TB, which works for everyone, everywhere.
“The Lancet Infectious Diseases article brings the spotlight back onto the challenges that are faced in developing the new antibiotics of the future, including for TB, as outlined in the WHO AMR Pipeline report. It is important that we all work together to ensure that the necessary investments are made into AMR R&D, particularly TB R&D, and to look for models, like The Life Prize, that ensure that the treatments of the future will be appropriately available to all,” said Grania Brigden, The Life Prize Project Lead, The Union.
The WHO report on the antibiotic pipeline – Antibacterial Agents in Clinical Development - an analysis of the antibacterial clinical development pipeline, including tuberculosis - can be downloaded here.